Lotus Yung

2.6k total citations
12 papers, 133 citations indexed

About

Lotus Yung is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lotus Yung has authored 12 papers receiving a total of 133 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lotus Yung's work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer Genomics and Diagnostics (4 papers) and Renal cell carcinoma treatment (3 papers). Lotus Yung is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cancer Genomics and Diagnostics (4 papers) and Renal cell carcinoma treatment (3 papers). Lotus Yung collaborates with scholars based in United States, United Kingdom and Spain. Lotus Yung's co-authors include Emil T. Lin, Chongsuk Ryou, Yong Huang, Pierre Lessard, Giuseppe Legname, Stanley B. Prusiner, B. Joseph Guglielmo, William Jacot, Dana B. Cardin and Andrew V. Biankin and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

Lotus Yung

12 papers receiving 130 citations

Peers

Countries citing papers authored by Lotus Yung

Since Specialization

Citations

This map shows the geographic impact of Lotus Yung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lotus Yung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lotus Yung more than expected).

Fields of papers citing papers by Lotus Yung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lotus Yung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lotus Yung. The network helps show where Lotus Yung may publish in the future.

Co-authorship network of co-authors of Lotus Yung

This figure shows the co-authorship network connecting the top 25 collaborators of Lotus Yung. A scholar is included among the top collaborators of Lotus Yung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lotus Yung. Lotus Yung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study 2023 ·Annals of Oncology ·Shanu Modi, William Jacot, Hiroji Iwata, Y.H. Park, María Vidal, (unknown), Junji Tsurutani, Khalil Zaman, Naoto T. Ueno, Aleix Prat, Konstantinos Papazisis, H. S. Rugo, Nadia Harbeck, S-A. Im, Michelino De Laurentiis, (unknown), Lotus Yung, (unknown), Yun Cheng, David Cameron	28
2	192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC) 2023 ·ESMO Open ·David Cameron, William Jacot, Toshinari Yamashita, María Vidal, Peter Schmid, (unknown), Michelino De Laurentiis, Flora Zagouri, Naoto T. Ueno, Aleix Prat, Nadia Harbeck, Rinat Yerushalmi, Yen‐Shen Lu, Andrea Gombos, (unknown), (unknown), Lotus Yung, (unknown), Junji Tsurutani, Shanu Modi	3
3	388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) 2023 ·Annals of Oncology ·Junji Tsurutani, William Jacot, Toshinari Yamashita, Farhan Riaz, Rinat Yerushalmi, S-A. Im, Naoki Niikura, (unknown), Javier Cortés, (unknown), Y.S. Chae, (unknown), Wěi Li, (unknown), Giovanna Masci, Emiliano Tamburini, (unknown), Kristen M. Tecson, Lotus Yung, Shanu Modi	10
4	Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1. 2019 ·Journal of Clinical Oncology ·Amod Sarnaik, Nikhil I. Khushalani, Jason Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Sajeve Thomas, Eric D. Whitman, Omid Hamid, Jose Lutzky, Anna C. Pavlick, Jeffrey S. Weber, James Larkin, Débora Barton, Lotus Yung, (unknown), Maria Fardis, John M. Kirkwood	24
5	APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC). 2016 ·Journal of Clinical Oncology ·Margaret A. Tempero, Dana B. Cardin, David Goldstein, Eileen M. O’Reilly, Philip Agop Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, Mingyu Li, Brian Lu, Andrew V. Biankin	9
6	P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT 2015 ·Annals of Oncology ·Margaret A. Tempero, Dana B. Cardin, Andrew V. Biankin, Daniel A. Goldstein, Malcolm J. Moore, Eileen M. O’Reilly, P. A. Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, (unknown), (unknown)	3
7	Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT) 2015 ·Gastroenterology ·Margaret A. Tempero, Dana B. Cardin, Andrew V. Biankin, David Goldstein, Malcolm Moore, Eileen M. O’Reilly, Philip Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, Mingyu Li, Brian Lu	1
8	nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT). 2015 ·Journal of Clinical Oncology ·Margaret A. Tempero, Dana B. Cardin, Andrew V. Biankin, David Goldstein, Malcolm J. Moore, Eileen M. O’Reilly, Philip Agop Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, (unknown), Brian Lu	1
9	APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA). 2014 ·Journal of Clinical Oncology ·Margaret A. Tempero, Dana B. Cardin, Andrew V. Biankin, David Goldstein, Malcolm J. Moore, Eileen M. O’Reilly, Philip Agop Philip, Hanno Riess, Teresa Macarulla, Lotus Yung, Xinyu Wei, Brian Lu	6
10	Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors 2013 ·Cancer Chemotherapy and Pharmacology ·Nianhang Chen, Sant P. Chawla, E. Gabriela Chiorean, William L. Read, (unknown), Alain C. Mita, Lotus Yung, (unknown), Richard McNally, Markus F. Renschler, Sunil Sharma	1
11	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma 2011 ·Cancer Chemotherapy and Pharmacology ·David A. Reardon, Timothy F. Cloughesy, Jeremy N. Rich, W.K. Alfred Yung, Lotus Yung, Clifford DiLea, (unknown), Margaret Dugan, William Mietlowski, Andrea Maes, Charles A. Conrad	11
12	Pharmacokinetics of quinacrine in the treatment of prion disease 2004 ·BMC Infectious Diseases ·Lotus Yung, Yong Huang, Pierre Lessard, Giuseppe Legname, Emil T. Lin, (unknown), Stanley B. Prusiner, Chongsuk Ryou, B. Joseph Guglielmo	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact